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It is generally accepted that acute renal hypertension, produced experimen- 
tally by constriction of the main renal arteries, is caused by the renin-angioten- 
sin  pressor  mechanism.  The  observation  that  chronic  experimental  renal, 
hypertension in the dog can be effectively prevented and treated by antirenin, 
actively produced in  or passively administered  to  the  animal  (1,  2),  lends 
considerable support to the view that this pressor mechanism may be operating 
actively even in the chronic stage of this disease.  Whether the pressor mecha- 
nism participates  in any way in the etiology of benign or malignant  human 
essential hypertension remains to be clarified, but the fact that in man, too, all 
the  constituents  of  the  renal  humoral  hypertensive  mechanism  have  been 
identified suggests that this mechanism may also play a part in human hyper- 
tension. One approach toward the elucidation of this problem was the study of 
the effect of the development of antirenin to heterologons renin in hypertensive 
patients  (3). Unfortunately, although antirenin produced in an animal is non- 
specific  for most other animals,  so that  antirenin  to heterologous renln  can 
partially inactivate the renin of other animals,  it has no effect on human renin. 
This is probably the explanation for the failure of the blood pressure to fall in 
hypertensive human beings with high titers of antirenin to hog renin (4). 
Since angiotensin is a polypeptide, active in man and all animals no matter 
what the source of the renin and angiotensinogen  used to produce the angio- 
tensin, there was reason to believe that an angiotensin inactivator, or inhibitor, 
might be effective in lowering  the blood pressure of hypertensive animals and 
perhaps of man. 
In an elucidation of the structure and the synthesis of angiotensin II,  the 
active  octapeptide  of  the  humoral  mechanism  (5-7),  it  became possible  to 
approach  the problem of producing an angiotensin  inhibitor  in a  systematic 
fashion.  A study of the structural  analogs of angiotensin would appear to be 
one  of the  promising  approaches;  but another,  which  was  adopted  for  this 
* Supported by Grant No. H1767, United States Public Health,  to Dr. Harry Goldblatt 
and Dr. Erwin Hass, and by the L. D. Beaumont Foundation, Cleveland. 
419 420  I~MUNOLOGIC  PRODUCTION  O]~ ANTIANGIOTENSIN.  I 
study,  is  the  immunological production  of  anti-angiotensin. Angiotensin II, 
like  most  polypeptides,  by itself,  appears  to  be  too  small  a  molecule  to  be 
antigenic.  It was  considered,  however,  that  coupling with  a  suitable protein 
carrier, might result in a  hapten-protein complex antigen which would induce 
the  development of an antibody capable of neutralizing the  biological action 
of angiotensin II. 
This report  describes  the  chemical  procedures  used  for  the  preparation  of 
the angiotensin-protein complex. Briefly the reactions involved were as follows: 
* Angiotensin II ~  p-nitrobenzoylangiotensin  II 
p-aminobenzoylangiotensin  II 
Benzoylangiotensin  II  4--  "diazonium salt" 
azo-BGG~; 
* Angiot~nsin//--unless otherwise specified, this refers  to the synthetic product valine  5- 
angiotensin II (aspartyl-~-amide). 
~; B GG-bovine-7-globulin. 
Materials  and  Methods 
ValineS-Angiotensin//.--This  was prepared synthetically as the aspartyl-/~-amide  deriva- 
tive. We are very grateful to Dr. Wettstein, Dr. Schwyzer,  and their colleagues of Ciba Re- 
search Laboratories, Basle, Switzerland, for making this compound available to us. Without 
their generous gift, this investigation would not have been possible.  The synthetic product 
has the identical amino acid sequence as that of naturally occurring, beef angiotensin II. 
The aspartyl-~-amide form has the same specific activity as the aspartyl-~-acid form (8). 
Bovine-7-globulin.--This  was  obtained  commercially  from  the  Armor  Laboratories, 
Kanakee, Illinois. 
Assay Procedures.--Bioassay of angiotensin II was carried out according to the procedure 
described  by Gotdblatt, Lamfrom, and Haas (9). A sample of angiotensin was injected intra- 
venously into a normal, trained, unanesthetized dog and the rise in the direct, mean, femoral 
blood pressure was determined. Pressor activity was then expressed  in terms of dog units, 
one unit being the quantity required to raise the pressure by 30 ram. Hg. 
Chemical Assay.--Color  reaction of the tyrosine residue in angiotensin II with Folin's 
phenol reagent (10) was used for assaying samples of angiotensin II in cases in which con- 
tamination with any other phenolic derivatives was not possible.  Free tyrosine and tyrosine 
bound in the peptide chain of angiotensin II were found to behave identically in their color 
reaction with Folin's phenol reagent. Optical density determinations were carried out at 550 
mtt with a  Coleman Junior spectrophotometer. 
Aromatic  Amine  Determination.--The  number of  aromatic  amine  residues  introduced 
per molecule of angiotensin II was determined by the ,*-naphthol procedure of Fantl (11) 
with slight modifications. Excess, solid sodium nitrite was added to a chilled (2 to 3°C.) solu- 
tion of the aromatic amine in 0.2 ~ HC1 and the excess HNO2 was later destroyed by the 
addition of solid ammonium sulfamate. After adjustment of the diazonium salt solution to a 
concentration of approximately 0.002 ~, 0.4 ml. of this solution was added to a mixture of 
0.4 ml. (20 micromoles)  of an alcoholic solution (95 per cent ethyl alcohol) of a-naphthol and 
0.2 ml. of 1 ~ NaOH. The deep,  red colored,  azo dye solution was diluted 1:40 with water 
and optical densities were read at 520 nag on the Coleman Junior spectrophotometer (8 x 8 x 
100 ram. cuvette). The amount of aromatic amine was determined by comparison with stand- SHARAD D.  DEODHAR  421 
ard solutions of p-aminobenzoylglycine; i.e., p-aminohippuric acid. The choice of the standard 
in this assay was made on the basis of the observation that the absorption spectrum at 480 
to 560 m# of the azo dye of p-aminobenzoylglycine is identical with the spectra of the corre- 
sponding azo products from p-aminobenzoyl derivatives of different peptides. The p-amino- 
benzoyl  derivatives  of  glutathione,  leucylglycine,  diglycylglycine, glycylglycine,  and  tri- 
glycylglycine were studied.  These were prepared  according to the procedures described by 
Landsteiner et al. (12, 13). Table I lists opticaa densities of the different azo products prepared 
by the procedure outlined above. It appears from the results in Table I  that  the nature of 
the peptide chain attached  to the p-aminobenzoyl radical has little or no influence on the 
light absorption at 520 In# of the final azo dye produced in this procedure. 
UV A bsorption Mea~urements.--The absorption spectra of b enzoylangiotensin II-azo-BGG 
and those of other aromatic diazo-BGG complexes were studied at room temperature with a 
Beckman (DU) spectrophotometer using quartz cuvettes with a light path d =  1.00 cm. 
TABLE I 
Determination  of Aromatic Amine Content of Different  p-Aminobenzoylpeptides 
Compound (p-aminobenzoyl  derivative  of)  Optical Density at 520 m# 
1.  Glutathione 
2.  Leucylglycine 
3.  Diglycylglycine 
4.  Glycylglycine 
5.  Triglycylglycine 
6.  Glycine 
0.64 
0.68 
0.69 
0.65 
0.68 
0.67 
0.4 ml.  (0.8 #u)  of a  0.002  M solution of the diazonmm salt of each compound used for 
the determination. 
EXPERIMENTAL 
Prepar~ion  of  p-Nitrobenzoylangiotonsin  II.--To a solution  of  0.I mM (105.3  rag.,  280,000 
dog units)  of  angiotensin  II in 10 mL of  water was added slowly  and with stirring  0.5 mM of 
p-nitrobenzoyl  chloride  in  0.5  mL of  ether.  The addition  was carried  out at  room temperature 
(25  to  27°C.)  over a period  of  90 minutes.  The reaction  mixture was kept alkaline  at  all  times 
by the  frequent  additions  of  small  amounts of 1  N NaOH  of  which a total  of  2 ml. was added 
by the end of the reaction  period.  The resulting  deep yellow colored  solution  was acidified 
(to  Congo red)  by the  addition  of  5 N HCI when a flocculent,  white precipitate  appeared.  The 
p-nitrobenzoic acid  present in this  precipitate  was removed by repeated extractions  with 
ether (7 to 8 extractions  with 25 ml. ether  each time).  The ether  layer  in each case  was dis- 
carded. Excess p-nitrobenzoic  acid was found to be completely removed by this  procedure 
leaving  behind the  precipitate  of  p-nitrobenzoylangiotensin  II  which was then filtered. 
Because of the small amount  of angiotensin II used in this preparation no 
attempt  was made  to purify or crystallize the product obtained after ether 
extraction. Total tyrosine content of the product at this stage was found to be 
80 per cent of the theoretical value. 
Preparation  of p-Aminobenzoylangiotem'in  //.--The  precipitate  of  p-nitrobenzoylangio- 
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alcohol and 1 ml. of concentrated  NH4OH (36 per cent NI-I3). The clear yellow solution ob- 
tained  in this manner was heated  to 65°C. and 3 m~ of powdered FeSO4, 7H20 was added 
slowly (15 to 20 minutes) and with vigorous stirring.  The resulting dark brown suspension 
was kept at 60°-65°C. for 45 minutes. The Fe (OH)s precipitate  was then centrifuged and 
the supernatant  containing  the p-aminobenzoylangioteusin  II was  evaporated  to dryness 
under vacuum. The residue was dissolved in 5 ml. of 0.2 N HC1 and the solution was analyzed 
for tyrosine and aromatic amine content by the respective assay procedures. 
Tyrosine content--0.065  m~ i.e. 65 per cent of the starting material 
Aromatic amine content--0.0949  m~ 
Aromatic amine 
Ratio, Tyrosine  (angioteusin II) =  1.46 
The ratio of aromatic amine to angiotensin II of 1.46 indicates that in the 
reaction  between  p-nitrobenzoyl  chloride  and  angiotensin  II  some  group(s) 
of the polypeptide chain, in addition to the terminal,  free amino group of the 
aspartic acid must be reacting. During this investigation no attempt was made 
to determine the location of this additional p-nitro (amino) benzoyl group. The 
guanidine group of arginine and the phenolic hydroxyl group of tyrosine would 
appear to be two possibilities in this respect, although the findings of Miller and 
Stanley  (14)  on benzoylation of tobacco mosaic virus suggest that under the 
conditions  of p-nitrobenzoylation  used  in  our  experiments  (pH  >  10),  the 
phenolic group probably, would not be esterified. 
Coupling of p-Aminobenzoylangiotensin  H  to BGG.-- 
To 4.5 ml.  (0.0585 n~) of p-amlnobenzoylanglotensin II solution in 0.2 N HC1 kept at 
2-3°C. was added an excess (1 mM) of solid, sodium nitrite slowly and the mixture was stirred. 
After 15 to 20 minutes, the excess HNO2 was destroyed by the addition of solid ammonium 
sulfamate and the solution was tested with starch-iodide paper. The diazonium salt solution 
was then added slowly to a solution of BGG (200 mg.) in 20 ml. of 0.25 ~r sodium carbonate 
buffer, pH 9.6. The solution rapidly turned an intense, orange red, indicating the formation 
of an  azo dye complex. Mter  standing  for  12  hours  at  2°C., the  solution  was dialyzed 
against  cold (2-3°C.), distilled water  for 48 hours.  Part of the protein  precipitated  during 
dialysis, but this could be redissolved by making the solution 0.1 ~r with respect to sodium 
phosphate  buffer, pH 7.4. The solution was sterilized, by passing it through a Seitz filter, 
and stored under sterile conditions. 
Absorption  Spectrum  of  Benzoylangiotensin  II-azo-BGG.--In  the  coupling 
reaction described above, the diazonium salt of p-aminobenzoylangiotensin II 
would be expected to couple primarily with the tyrosine and histidine residues 
of BGG. The formation of an azo dye complex is indicated by the characteristic 
intense,  orange-red color of the resulting  solution.  Another indication  of the 
formation of this azo dye complex was derived from a comparison of its absorp- 
tion spectrum with that of the azo complexes between several para substituted, 
aromatic amines, and BGG. These azo complexes were prepared in the following 
manner: 0.5  ml.  (0.5  micromole)  of a  diazonium salt  solution prepared  from 
each of different aromatic amines was added to a  solution of BGG (10 rag. in SHARAD  D.  DEODHAR  423 
1.2 mt. of 0.25 M sodium carbonate buffer, pH 9.6) and the azo-protein complex 
was treated as before. 
Figs. 1 and 2 illustrate absorption spectra (250 to 500 m/~) of these different R- 
phenyl-azo-BGG (R =  para substituent) preparations studied in 0.1 M sodium 
phosphate buffer, pH 7.4. The ordinate in this figure represents optical density 
of a solution of the azo complex which is 10  4  ~  with respect to concentration 
of the aromatic amine. 
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FIG.  1.  Absorption spectra of R-pheayl-azo-BGG comp]exes. X ......  X, su~amilic acid; 
0  O,  p-aminobenzoylangiotension  II;  B---E],  p-aminobenzoic  acid; • ......  •, 
BGG alone. 
For comparison, Fig. 1 also shows the absorption spectrum of a  solution of 
BGG carried in equivalent amounts through the entire procedure except for the 
addition of aromatic amine. It is apparent from these figures that introduction 
of the diazo linkage between an aromatic amine and BGG imparts a characteris- 
tic absorption spectrum to the complex. The nature of the substituent in the 
para position of the aromatic amine has more of a quantitative than qualitative 
effect on  the  absorption  spectrum.  Since p-aminobenzoylangiotensin II  and 
BGG react to give a product with a similar absorption spectrum, the formation 
of a diazo linkage between the two is indicated. 
Biological Activity of Angiotensin II Derivatives.--Table  II shows the bio- 
logical activity (dog units per millimicromole of angiotensin II)  of different 
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FIG. 2.  Absorption  spectra  of R-phenyl-azo-BGG  complexes. 0----0,  p-aminoaceto- 
phenone;  X ......  X,  p-aminohippurlc  acid;  •  ......  0,  aniline;  []  [],  p-anisidine. 
TABLE II 
Biological Act~ty  of Angiotensin II Derivatives 
Biologic~l  activity,  dog 
Compound  No.  of  deter-  units/millimicromole  minations  Tyrosine 
1.  Angiotensin II (aspartyl-#-amide) ................ 
2.  Angiotensin II (aspartyl-~-acid) ................. 
3. p-Nitrobenzoylangiotensin  II  .................... 
4. p-Aminobenzoylangiotensin II  .................. 
5.  After coupling with BGG ...................... 
14 
8 
4 
6 
5 
2.80  4- 0.2 
2.84  ±  0.21 
1.2  4- 0.14 
1.2  4- 0.13 
0.1  -¢- 0.O23 
* Standard  deviation. 
It was shown in control experiments that under the conditions of the coupling 
procedure non-specific inactivation of angiotensin II can be ruled out. A  sam- 
ple of angiotensin II was carried through the entire procedure,  except  for the 
addition of p-nitrobenzoyl chloride, and was found to retain its original  specific 
activity and 70 to 80 per cent of its total, initial activity. Therefore, the lower 
activity of p-nitro and p-aminobenzoylangiotensin II as  compared  to that  of 
angiotensin II must be attributed  to the introduction  of the p-nitro  (amino) 
benzoyl group. It was indicated  previously that in the  p-nitrobenzoylation of SHARAD D.  DEODHAR  425 
angiotensin  II some group(s) in addition to the free,  terminal  amino  group of 
aspartic acid appeared to be reacting.  The observation that  p-nitro  (amino) 
benzoylangiotensin II prepared under these conditions retains about 40 to 50 
per cent of the biological,  specific activity of the parent compound indicates 
that the presence of a free, terminal amino group is not an absolute requirement 
for the pressor action of angiotensin II. 1 This property of angiotensin II distin- 
guishes it from angiotensin I since in the latter case, presence of a free, terminal 
amino group appears to be essential.  Thus Braun-Menendez et al. (15) have re- 
ported that benzoylation of crude preparations of angiotensin by the Schotten- 
Bauman  procedure  resulted  in  a  complete  loss  of  activity.  Although  the 
distinction  between angiotensin  I  and  angiotensin  II was not known at  the 
time of this report, it would appear from their procedures that they were very 
likely dealing with angiotensin I. Using a partially purified preparation of horse 
angiotensin I  (obtained through the courtesy of Drs.  Skeggs and Kahn,  Crile 
Veteran's Administration Hospital, Cleveland--purity 50 per cent, on the basis 
of dog units/rag.  N) we have also observed that  the introduction of p-amino- 
benzoyl groups under conditions identical with those used for angiotensin  II, 
results in a complete loss of activity. Aside from the obvious possibility that 
this  may  be  caused  by certain  impurities  in  the  starting  preparation,  one 
may explain this difference in the behaviors of angiotensins I and II on the basis 
of the known enzymatic mechanisms involved in the formation of angiotensin II, 
the active pressor! substance.  It was shown by Skeggs  et al.  (16) that angio- 
tensin  I,  the initial  product  of renin-angiotensinogen  interaction,  is not the 
active pressor substance but that it assumes this property only after conversion 
to angiotensin  II,  as catalyzed by the  "converting enzyme." It is  therefore 
possible that,  for the action of the converting enzyme, the presence of a free 
amino group(s) in angiotensin I is essential; on the other hand, the specificity of 
the receptor site for angiotensin  II may be such that the presence of the free, 
terminal amino group is not an absolute requirement. 
Coupling  of the diazonium salt  of p-aminobenzoylangiotensin II with BGG 
results in a tenfold decrease of its pressor activity. It has not yet been deter- 
mined whether this small,  residual activity truly represents the pressor action 
of benzoylangiotensin II-azo-BGG or whether this merely represents contami- 
nation with (a) uncoupled p-aminobenzoylangiotensin II diazonium salt that 
was not removed by dialysis or (b) intermolecular benzoylangiotensin II-azo- 
benzoylangiotensin II complex which  may be formed by the coupling  of the 
diazonium salt with the tyrosine or histidine residue in the polypeptide chain of 
angiotensin II. During this investigation, no attempt was made to fractionate 
1 Dr. Schwyzer and his coworkers at Ciba Ltd., Switzerland, have recently sent us a sample 
of p-aminobenzoylangiotensin II prepared by total synthesis starting from p-aminobenzoyl- 
aspartic acid (/5-amide). From our assay procedures this compound was found to have aromatic 
amine to tyrosine ratio of 1.0 and a specific activity of 1.4 dog units per millimicromole. 426  IMMUNOLOGIC  PRODUCTION  O:F ANTIANGIOTF.NSIN.  I 
the benzoylangiotensin II-azo-BGG preparation and it  was used for immuno- 
logical studies without further purification. 
SUMMARY 
Angiotcnsin II was coupled with bovine "},-globulin  (BGG)  through the fol- 
lowing series  of reactions. 
Angiotensin II  ......... -p-nitrobenzoylangiotensin II 
Benzoylangiotensln  H-azo-BGG  p-amlnobenzoylanglotensin  II 
\  / 
"diazonlum  salt" 
By determinations of the aromatic amine and tyrosine  contents of p-amino- 
bcnzoylangiotensin If, the number of p-aminobcnzoyl residues  introduced per 
molecule of angiotcnsin II was calculated. 
Absorption spectra (between 250 and 500 m/z)  of  BGG  complexes of  p-amino- 
benzoylangiotcnsin II and six different  part substituted aromatic amines wcrc 
compared. 
Specific activities (dog units/millimicromole) of the different  intermediate 
products were determined. Presence of a terminal, free  amino group does not 
appear to bc an absolute requirement for the biological  activity  of angiotensin 
II, since  substitution  of a p-aminobenzoyl radical  in this  group yields  a product 
with 40 to 50 per cent of the activity  of the parent compound. Angiotensin I, 
on the other hand, is completely  inactivated under identical circumstances. 
Possible  implication  of  this  finding  has been discussed. 
The author wishes to  express  his  slnccre  appreciation to Dr. Harry Goldblatt and Dr. Erwin 
Haas for their  suggestion  of this  problem  and their  guidance  throughout  the course  of this 
work and in the  prcparatlon  of  this  manuscript.  The competent  technical  assistance  of  Mrs. 
Mary Picken  and Mr. James Malone is  gratefully  acknowledged. 
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